| |
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
Today’s Big NewsJan 24, 2024 |
| By Gabrielle Masson Eli Lilly says an investigational gene therapy has restored hearing in one child who has experienced hearing loss since birth. |
|
|
|
By Max Bayer BenevolentAI has named longtime pharma exec Joerg Moeller as its new CEO. He previously led R&D at LEO Pharma after nearly two decades at Bayer. |
By Nick Paul Taylor A group of familiar faces to Incyte watchers has broken off to start their own biotech, pulling in $102 million to develop competitors to approved cancer drugs from AstraZeneca, GSK, Novartis and Pfizer. |
Sponsored by Cardinal Health Cell and gene therapy patients often require support throughout their treatment journey. Learn key considerations for developing patient support programs. |
By James Waldron The winding journey of Annovis Bio’s potential Parkinson’s disease therapy through the clinic isn’t over quite yet, with the biotech revealing today that much-anticipated phase 3 data won’t be published this month as planned. |
By Nick Paul Taylor Genome & Co. has shared data from a midphase that is testing its bacterial strain in combination with a checkpoint inhibitor. The readout encouraged the biotech to plan further clinical trials to validate the combination as a third-line treatment. |
By Helen Floersh Amphista Therapeutics has new data demonstrating the potential of its protein degraders in animal models, a step toward bringing the tech to the clinic. |
By Fraiser Kansteiner Shortly after its spinoff and IPO, WuXi Biologics’ subsidiary WuXi XDC has locked up a major customer on its quest to establish itself as a premier bioconjugation contract research, development and manufacturing organization. |
By Joseph Keenan In a move to expand its footprint, iuvo BioScience, which describes itself as a specialty partner research organization, has picked up ophthalmology-focused CRO Promedica International. |
By Conor Hale Worldwide operational sales across J&J’s medical device divisions grew 12.4% in 2023, to top $30.4 billion in total revenue, with Abiomed alone contributing 4.7%, the company said. |
By Joseph Keenan Pharma giant GSK and Elegen are partnering to leverage the California-based DNA manufacturer's proprietary technology to help develop new vaccines and medicines. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Sofia Guerra and Steve Kraus from Bessemer Venture Partners sat down with Fierce Healthcare's Heather Landi to discuss the health tech sector's performance, unraveling the factors that contributed to its current state. They share what it will take to get health tech out of its current market lull and explore whether we’ll see a rebound in IPOs this year. |
|
|---|
|
|
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
